Updated:
Castle Biosciences
Castle Biosciences was founded in 2007 in Arizona before relocating its headquarters to Friendswood, Texas.
Castle Biosciences
Castle Biosciences was founded in 2007 in Arizona before relocating its headquarters to Friendswood, Texas. Derek Maetzold, who remains president and CEO, built the company around the idea that genomic testing could definitively answer clinical questions that traditional pathology left ambiguous. The company went public on Nasdaq in July 2019 under the ticker CSTL. Castle's business is the development and commercialization of proprietary gene expression profile tests. The firm's dermatology portfolio includes DecisionDx-Melanoma, which predicts metastatic risk for cutaneous melanoma, and DecisionDx-SCC, aimed at squamous cell carcinoma. In gastroenterology, the company sells DecisionDx-Gastric for peritoneal malignancies. A mental health initiative includes IDgenetix, a pharmacogenomic test guiding antidepressant selection. These are not fund positions; they are internally developed products sold to clinicians, with revenue recognized per test. The firm also conducts outcomes research through collaborations with academic centers, including the Mayo Clinic. The geographic footprint is limited to the United States, though select research collaborations extend to other countries. The company employs roughly 660 people as of its most recent filings. In fiscal year 2023 it delivered test reports for approximately 114,000 patients, more than double its volume from 2020. Adjacent to its core business, Castle operates a clinical laboratory network and a biostatistics unit that supports published clinical validation studies. The firm has no disclosed foundation or philanthropic vehicle separate from its corporate structure. Castle's structural differentiator is a centralized lab model built on a proprietary biorepository and clinical outcomes database — the company does not license third-party biomarkers. This closed-loop R&D model, paired with Medicare coverage for several lead tests, creates a narrower but highly defensible commercial moat than diversified diagnostic conglomerates.
General information
Firm type
Asset Manager
Year founded
2007
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Friendswood
Corporate office
Friendswood, TX, United States
Principals
Derek Maetzold
President, Chief Executive Officer & Director
Sector focus
Frequently asked questions
Who runs investment and strategic decisions at Castle Biosciences?
Derek Maetzold, the company's founder, runs the business as president and chief executive officer. A board of directors including independent members oversees governance. As an operating company rather than a fund, capital allocation decisions follow standard corporate planning processes.
Is Castle Biosciences a family office or an investment vehicle?
No. Castle Biosciences is a publicly traded molecular diagnostics company listed on Nasdaq. It generates revenue by selling proprietary diagnostic tests, not by managing third-party capital or a family's assets.
What is Castle's core product?
DecisionDx-Melanoma is Castle's flagship assay, used to predict the risk of metastasis and sentinel lymph node positivity in patients with cutaneous melanoma. The test is covered by Medicare and has been validated in multiple peer-reviewed publications.
Does Castle Biosciences participate in fund commitments or direct investments in other healthcare companies?
Castle does not operate as a fund or strategic investor. Its capital deployment goes toward internal R&D pipeline expansion, laboratory infrastructure, and commercialization of its own diagnostic products rather than external company stakes.
What is Castle's known posture on co-investments alongside external GPs or allocators?
As a Nasdaq-listed operating company, Castle does not engage in co-investments. It occasionally collaborates with industry peers on research studies, but those are scientific rather than financial partnerships.
Where does the underlying wealth or capital for Castle Biosciences derive from?
Capital originated from venture funding prior to its 2019 IPO and now from public markets. Castle does not manage fortunes. It is a commercial-stage life sciences company whose shareholders are the owners of its equity.
How does Castle source its proprietary deal flow or pipeline candidates?
Castle's pipeline is built through internal biomarker discovery and validation rather than external acquisitions. New tests are typically developed using its archived clinical samples and longitudinal outcomes database, a closed-loop R&D model that reduces reliance on in-licensed intellectual property.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: